Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

33 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05954143 2025-11-20

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Phase 2 Terminated

11 enrolled 13 charts

Breast

Breast Neoplasms

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase 2 Terminated

64 enrolled 21 charts

Breast

Breast Neoplasms

NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Phase 2 Terminated

26 enrolled

Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

NCT04504916 2025-11-10

MK-2140-002

Phase 2 Terminated

102 enrolled 36 charts

BreastGastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Breast

Triple Negative Breast Neoplasms

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04136912 2025-10-06

3-D Super Resolution Ultrasound Microvascular Imaging

Phase 2 Terminated

27 enrolled 12 charts

BreastHead & Neck

Breast Neoplasms, Thyroid Neoplasms

NCT04659603 2025-10-01

CARMEN-BT01

Phase 2 Terminated

50 enrolled 20 charts

BreastGastrointestinal

Breast Cancer Metastatic

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

6 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03535506 2025-09-26

WI223281

Phase 2 Terminated

17 enrolled 9 charts

Breast

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04191382 2025-09-18

AMEERA-4

Phase 2 Terminated

105 enrolled 16 charts

Breast

Breast Neoplasms

NCT04249622 2025-09-16

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Phase 2 Terminated

20 enrolled 13 charts

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT07166367 2025-09-10

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

Phase 2 Terminated

3 enrolled

Breast

HER2-positive Breast Cancer

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2 Terminated

17 enrolled 16 charts

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT01703754 2025-08-28

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

Phase 2 Terminated

12 enrolled 24 charts

Breast

Breast Neoplasms

NCT03862131 2025-07-29

PROACT

Phase 2 Terminated

49 enrolled 12 charts

BreastLymphoidOther hematologic neoplasmPlasma cellSarcomaThoracic

Breast Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Sarcoma, Neoplasms, Plasma Cell, Cardiotoxicity

NCT04227327 2025-07-29

HERMIONE-7

Phase 2 Terminated

31 enrolled

Breast

Advanced Breast Cancer

NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Phase 2 Terminated

25 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

253 enrolled 21 charts 2 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04720729 2025-06-22

MONDRIAN

Phase 2 Terminated

160 enrolled

Breast

HER2-negative Metastatic Breast Cancer

NCT04789096 2025-06-06

TUGETHER

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms

NCT04251169 2025-06-03

TATEN

Phase 2 Terminated

20 enrolled 19 charts

Breast

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Phase 2 Terminated

52 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00538343 2025-05-29

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Phase 2 Terminated

14 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00195091 2025-05-16

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Phase 2 Terminated

16 enrolled 5 charts

Breast

Breast Neoplasms

NCT04965688 2025-04-10

SPOCK

Phase 2 Terminated

2 enrolled 4 charts

Breast

Breast Neoplasms

NCT04383210 2025-04-03

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Phase 2 Terminated

54 enrolled 11 charts

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fibromatosis, Gingival, 2, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Uterine Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05336721 2025-03-24

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Phase 2 Terminated

9 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Breast

Triple Negative Breast Neoplasms

NCT04440982 2025-01-15

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Phase 2 Terminated

98 enrolled

Breast

Breast Neoplasms

Clinical Trials

TRANSCENDER

Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

VEnT

AMTEC IIT: Phase 2 Multiarm Study in TNBC

AMEERA-3

Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer

INTEGRAL

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases

neoMono

ELPIS

Olinvacimab With Pembrolizumab in Patients With mTNBC

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

ATRA

TrasTUCAN

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

BIS-Program

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

MK-2140-002

ELEVATE TNBC

PAVO

TNBC

3-D Super Resolution Ultrasound Microvascular Imaging

CARMEN-BT01

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

WI223281

AMEERA-4

Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

PROACT

HERMIONE-7

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

DESTINY-Breast01

MONDRIAN

TUGETHER

TATEN

PERSEVERE

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

SPOCK

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients